While mobile elements are largely inactive in healthy somatic tissues, increased activity has been found in cancer tissues, with significant variation among different cancer types. In addition to insertion events, mobile elements have also been found to mediate many structural variation events in the genome. Here, to better understand the timing and impact of mobile element insertions and mobile element-mediated structural variants in cancer, we examined their activity in longitudinal samples of four metastatic breast cancer patients. With whole-genome sequencing data from multiple timepoints through tumor treatment and progression, we used mobile element detection software followed by visual confirmation of the insertions. From this analysis we identified 11 mobile element insertions or mobile element-mediated structural variants, and found that the majority (nine of the eleven) of these occurred early in tumor progression. Two of the identified insertions were SVA elements, which have not been examined in previous cancer studies. Most of the variants appear to impact intergenic regions; however, we identified a mobile element-mediated translocation in MAP2K4 and a mobile element-mediated deletion in YTHDF2 that likely inactivate reported tumor suppressor genes. MAP2K4 is part of the JNK signaling pathway, influencing cell growth and proliferation. The high variant allele frequency of this translocation and the important function of MAP2K4 indicate that this mobile element-mediated translocation is likely a driver mutation.
Introduction
Mobile elements, or transposable elements, are segments of DNA that are capable of mobilizing from one genomic location to another. These elements compose a significant portion to be quite variable in patients with the same type of cancer, and also shows a high degree of variability among cancer types (Helman et al. 2014; Tubio et al. 2014) . Regardless of cancer type, roughly half of all tumors have at least one somatic L1 insertion (Tubio et al. 2014) .
The impact of mobile elements on the cancer genome is not limited only to somatic insertions, but also includes the structural variation (SV) events that they mediate (reviewed in Cordaux and Batzer 2009) . Notably, mobile elements mediate roughly 10% of all SV events over 100 base pairs long found in the human genome (Xing et al. 2009 ). Mobile elements have been found to mediate SV events that can lead to cancer development (Mauillon et al. 1996; Hsieh et al. 2005) . For example, approximately 42% of the BRCA1 gene is composed of Alu elements (Welcsh and King 2001) , making this gene a target for non-allelic homologous recombination, specifically Alu-Alu mediated events (Petrij-Bosch et al. 1997; Puget et al. 1997; Rohlfs et al. 2000; Peixoto et al. 2013) . L1 transduction events have also been examined in a variety of cancers (Tubio et al. 2014) .
Multiple studies have shown that L1s, in particular, demonstrate increased retrotransposition activity in cancer tissues. However, the timing of these insertions or mobile element-mediated SVs has not been thoroughly investigated. Additionally, L1s and the structural variants that they mediate have been the focus of most previous studies, with little focus on the impact of Alu and SVA insertions or the SVs they mediate. In this study, we utilize longitudinally sampled breast cancer tissues to better understand the timing and significance of increased mobile element activity on the cancer genome.
Results
To analyze mobile element activity during tumor progression, we used longitudinal whole-genome sequencing (WGS) data from four metastatic breast cancer patients. Tumor samples were obtained from these patients over multiple years (2-15 years) with varying WGS and bulk RNA-seq timepoints (2-6) available for our analyses. Germline DNA was sequenced from the blood of each patient. The WGS timepoints for each patient, and a summary of treatment information over time, are shown in Figure 1 . More detailed treatment information for each patient can be found in the supplementary information of Brady et al. 2017 . All four patients were estrogen receptor (ER) +. Patients 1 and 2 were human epidermal growth factor receptor 2 (HER2) +, while Patients 3 and 4 were HER2-. Figure 1 . Outline of patient treatment information. Parts A-D correspond with patients 1-4, respectively. Each medication or treatment is identified by a colored box. The length of the box approximates the duration of each treatment. If multiple treatments overlapped, the boxes are stacked through the timepoints for which they overlapped. The timepoint of each sampling event is shown on the top of the box in days after the first sampling timepoint. *= DNA, **= DNA and RNA, †= RNA We analyzed each of the four patients for mobile element insertions utilizing three tools (MELT, TranSurVeyor, and RUFUS, further described in the Methods section). After identifying and filtering mobile element insertions and SVs (see Methods), we generated a list of potential insertion sites. These potential insertion sites were compared to the matched germline sample for each patient to ensure that the insertion identified was a somatic event. Timepoints for each patient were analyzed individually and compared to the matched germline sample. Following our identification and filtering steps, we were able to identify mobile elements and associated variants at both very high VAF (100%) and very low VAF (~5%).
Collectively, we identified seven mobile element insertions and four structural variants that were mediated by mobile elements in tumor samples. These variants all appear to be somatic mutations acquired during tumorigenesis or during tumor progression because these variants are not present in the corresponding germline samples. The variants that we have identified in each of the four patients are summarized in Table 1 . We find that the majority of insertions and variants associated with mobile elements (nine of the eleven) occur before the first sampling timepoint, because these were already present in the first and then all subsequent samples. The two variants that were not present in the first sampling timepoint were both SVA insertions. We also find high variability in the number of insertions and variants that were identified in each of these patients, with three of the patients (Patients 1, 2, and 4) showing multiple insertions and variants, and Patient 3 showing only a single mobile element mediated structural variant. The use of multiple tools and visual inspection for the identified insertions excluded a number of false positive calls. To prevent false negative calls for variants with low frequency, the recommended filters for each tool were not used. Instead, calls made for each timepoint were compared to the matched germline sample. With this filtering, only the mobile elements unique to the tumor sample remained. After filtering, MELT identified 17,704 potential mobile element variants, and TranSurVeyor identified 69,388 potential mobile element variants. Counts for the images produced by RUFUS were not included here as RUFUS is designed to detect many types of variants, not exclusively mobile elements.
Most of the identified insertions and variants were found in intergenic regions and are unlikely to impact gene expression as they do not overlap known regulatory or ultra-conserved regions. However, we identified multiple insertions that appeared to impact intronic regions: an SVA insertion in CCT4, which was identified in Patient 1, and an L1 insertion in ANKRPD26P, which we identified in Patient 2. We also identified two Alu-mediated somatic structural variation events that impact exons in two genes: an Alu-Alu mediated deletion in YTHDF2 and an Alu-mediated translocation impacting MAP2K4. Both of these Alu-mediated structural variants occurred in Patient 1 and occurred before the first sampling timepoint, but were not present in the germline sequencing data. To remove contamination from non-tumor cells, we estimated the tumor purity (or cancer cell fraction) of each timepoint. The purity estimates, as well as estimates for genomewide copy number for each timepoint in each patient, are included in Table 2 . There are many changes in genomic copy number, with genome-wide estimates ranging from 1.86, just below normal cellular copy number, up to 4.12, more than twice that seen in most normal cells. In these patients, tumor purity ranged from 30.91% to 94.5%, with a mean value of 76.25%. The only formalin-fixed, paraffin-embedded (FFPE) sample in the dataset had the lowest tumor purity value. We calculated the variant allele frequencies (VAF) for each of the mobile element insertions or SVs identified after adjusting for tumor purity ( Figure 2 ). The VAFs calculated from the adjusted data are slightly higher, but very similar to the VAFs calculated from the unadjusted VAFs ( Figure S1 ). Of the four insertions and SVs identified in Patient 1 (Figure 2A ), the Alu-Alu mediated deletion in YTHDF2 and the translocation in MAP2K4 were present at very high frequency (>80% for the deletion; 100% for the translocation) at the first timepoint, with decreased frequency over time. The other two identified events were insertions (an Alu and SVA) and were present at much lower frequencies. The SVA identified in this patient was not present at the first two sampling timepoints but is present by the third and remained in the tumor cells in the fourth sampling timepoint. Each of these events show a slight decrease over sampling timepoints. We identified three somatic insertions in Patient 2 ( Figure 2B ), two L1 insertions, and one Alu insertion. The L1 insertion on chromosome 13 was present at a higher frequency than the other two insertions found in this patient. The frequency of these variants closely resembles the frequency of the mobile element insertions seen in Patient 1, but does not reach the high frequency seen in the translocation or deletion of Patient 1.
Of the four individuals sampled, Patient 3 ( Figure 2C ) had the fewest variants, a single TE-mediated deletion, which appears to be an Alu-Alu mediated deletion. This deletion was present at a high frequency in the first sampling timepoint (present in about 75% of reads), but decreased to approximately 50% by the second sampling timepoint. In Patient 4 ( Figure 2D ), we identified two insertions, an Alu and SVA, and a single mobile element-mediated SV, a L1-L1 mediated deletion (L1MD). The first sequenced sampling timepoint for Patient 4 has been excluded in the VAF plot as it was a FFPE sample, decreasing our ability to accurately calculate a VAF for this timepoint. The SVA insertion identified in this patient was not present for the first sampling timepoint, but was present for the next two sampling timepoints. By the final sampling timepoint the SVA was no longer observable in the sequencing data. The L1MD trends upward in VAF before sharply falling at the final timepoint. The Alu insertion in this patient appears to maintain a steady VAF of ~20%. Figure 2 . Adjusted variant allele frequency (VAF) for each of the 4 patients. Parts A-D correspond to patients 1-4, respectively. The VAF for each patient has been adjusted to better reflect the percentage of cells in the sample that appear to be from the tumor. VAF is shown on the Y axis with each sampling timepoint for a particular patient shown on the X axis.
After identifying the mobile element insertions and the SVs that they mediate in these four patients (Table 1) , we analyzed the impact of these variants on the cancer genome. Because both variants that impacted exons were found at high frequency in Patient 1, we examined the genomic copy number present at these loci. Specific genome-wide copy number estimates for the first timepoint in the genome of Patient 1 are shown in Figure 3 . Both the Alu-Alu mediated deletion and the Alu mediated translocation appear to have been reduced to only a single copy, contributing to the high frequency for both. Figure 3 . Copy number estimates from FACETS for Patient 1. The approximate location of the deletion in the YTHDF2 gene is shown in the green box. The approximate location of the breakpoint for the MAP2K4 translocation that appears to be mediated by Alu elements are shown in the purple box on chromosome 17. Both events occurred in regions that have a decreased copy number. The black lines in the figure represent the total copy number, while the red lines show the minor copy number for each segment.
Due to decreased copy number at the MAP2K4 locus, and the translocation interrupting the one remaining copy of MAP2K4 (a depiction of this translocation is shown in Figure 4A ), we validated absence of the complete transcript and protein in the cancer cells of Patient 1. Creating a de novo transcript assembly of RNA-seq data for each timepoint in Patient 1 (see Methods), we find only truncated transcripts of MAP2K4. For further validation of lack of protein production by MAP2K4 in the tumor cells of Patient 1, we performed a Western blot using HEK293T cells as a control and tumor cells taken from an ascites sample from Patient 1 ( Figure 4B ). While the control cells show clear production of MAP2K4, there appears to be no MAP2K4 being produced in the tumor cells of Patient 1. Mobile elements can be divided into subfamilies, classified by diagnostic mutations. As different subfamilies may have different expression patterns in cancer, we examined these subfamilies in our patients. Three of the patients in this study had longitudinal bulk RNA-seq data available for further analysis (Figure 1 ). There was no germline RNA-seq data available for these patients, but using SQuIRE we were able to analyze mobile element expression on both subfamily (examining all mobile element transcripts from one mobile element subfamily) and locus-based (specific mobile element loci) levels throughout tumor progression Table S1 . At the single-locus level, by comparing the four earliest timepoints of Patient 2 to the latter two timepoints (1016 days; nearly 3 years between the fourth timepoint and the fifth), we see significant expression changes (adjusted pvalue < 0.05), both increases and decreases, for 337 loci. 125 of these loci are Alu elements, 123 are L1s, and 16 are SVA insertions. The remaining loci largely belong to older mobile elements and LTR families. The complete list of mobile element loci that show significantly different expression over time are shown fully in Table S2 .
The 264 L1s, Alu elements, and SVAs that were found to be differentially expressed between the first set of timepoints and second set of timepoints in Patient 2 were intersected with a list of regulatory regions in mammary epithelial tissue. Of these 264 mobile elements, 72 overlapped with a total of 87 regulatory regions. These 87 regulatory regions include a number of CCCTC-binding factor (CTCF) binding sites, open chromatin regions, promoter flanking regions, as well as several enhancers, promoters, and transcription factor binding sites. These overlaps are shown in Supplemental Table S3 .
Discussion
Using a trio of mobile element and de novo variant detection tools, we identified mobile element insertions and variants in longitudinal WGS data from four breast cancer patients ( Figure 1) . We also find that the visual validation step (IGV or other similar tools) used here reduces the risk of false positive calls and significantly improves the overall accuracy of variant calls (similar to Feusier et al. 2019) . This is particularly important for cancer genomes, because most mobile element detection software is not designed for the complexity of a cancer genome.
This increased complexity makes the visual inspection step necessary, as there were thousands of potential mobile element insertions suggested by these programs that were not unique to the somatic cells, or were the result of mis-mapping in low complexity or mobile element-rich regions. However, the calls from these programs that passed visual inspection spanned both high variant allele frequency and very low variant allele frequency (Figure 2) , showing that the insertions or variants did not have to be present at a particularly high frequency to be detected.
The VAFs for each event change at each timepoint, reflecting the change in subclone frequency shown previously (Brady et al. 2017) . Large changes in VAF shown in the current study generally correlate with bottleneck events or large shifts in subclone frequency found previously (Brady et al. 2017 ). The insertions that share similar VAF may be from the same tumor subclone (see the Alu insertion and L1 insertion on chromosome 8 in Patient 2) ( Figure   2B ), and, after adjusting for tumor purity, those that still show a sharp decline in VAF are likely part of a tumor subclone that showed decreased frequency. The insertions and variants that are present at very high frequency (near 100%) are likely mutations that occurred early in cancer development. In cancers with a greater number of these events, mobile elements may be valuable markers for identifying tumor subclones, similar to their role in population genetics and evolutionary studies. Using these markers in conjunction with SNPs may increase the level of resolution possible for tumor subclones.
From the summary of the insertions and mobile element mediated SVs identified in four patients (Table 1) , we show activity for not only L1s, which we expect based on previous literature (Lee et al. 2012; Tubio et al. 2014; Doucet-O'Hare et al. 2016 ), but also activity from Alu and SVA elements. Most previous studies have largely focused on L1s and the structural variants that they mediate (Helman et al. 2014; Tubio et al. 2014 ), though others have identified a small number of Alu insertions (Lee et al. 2012 ). SVA has not been a target for most previous studies, but recent work also supports post-zygotic insertions in normal tissue for this mobile element family (Feusier et al. 2019) . We also see variation among patients, with most individuals showing multiple insertions or variants but one showing only a single event that appears to be Alu-Alu mediated.
The majority of the variants identified in this study appear to occur early in our samples (Table 1, Figures 2 and 3 ) and likely early in tumor progression or development. As the bulk of these events occur early, it would suggest that mobile elements are likely more active early in cancer, and could play a role in tumorigenesis. This supports previous work done in metastatic tumors from multiple patients showing that most of insertions that occurred in the primary tumor were reflected in metastases (Ewing et al. 2015) . In addition to the early insertions and SVs we identified, we find two insertions, both SVAs, that insert later in tumor progression. It is unclear if there is something unique about SVA insertions that would cause them to be more active later in cancer, or if this is just a result of our small sample size. Future studies with a larger sample size of patients should attempt to identify these insertions to determine if the trend of insertions at later timepoints remains.
The early SV events identified in Patient 1 both appear to be Alu-mediated and to affect the coding sequence. The affected genes (MAP2K4 and YTHDF2) , have both been implicated in cancer development (Su et al. 2002; Ahn et al. 2011; Koboldt et al. 2012; Xue et al. 2018; Zhong et al. 2019) . The deletion we uncovered in YTHDF2 removes the final exon that would be present in the primary transcript. Though there have been reports of this gene acting as a tumor suppressor, it is not listed in the Catalogue of Somatic Mutations in Cancer (COSMIC) (Tate et al. 2018) , and further work likely needs to be completed to validate its role in cancer. The translocation that we identified in Patient 1 interrupted MAP2K4, a gene with far more supporting evidence that suggests it plays a role in catalyzing tumor development or metastasis (Ahn et al. 2011; Pavese et al. 2014) . The breakpoint on chromosome 17 for this translocation occurs after the third exon of MAP2K4 ( Figure 4A) , with a number of mobile elements present in this region. The breakpoint on chromosome 22 disrupts an Alu element, and it is likely that this translocation was mediated by an Alu-Alu interaction, or by the interaction of other repetitive elements in the region surrounding the breakpoints. There have also been previous examples of Alu-mediated translocations and recombinations in cancer (Onno et al. 1992; reviewed in Elliott et al. 2005) . MAP2K4 is listed in COSMIC as potentially having a role in both tumor suppression and as an oncogene, depending on its expression level.
We find decreased copy number along multiple regions of chromosome 17, including the region that contains MAP2K4 (Figure 3 ). With only a single copy of this gene remaining, the translocation renders it inactive, leading to the lack of production of the protein that we see from the Western blot ( Figure 4B ). Further analysis of the RNA-seq data for this patient showed that there were no complete transcripts for MAP2K4, with no evidence for fusion transcripts being produced as a result of the translocation. MAP2K4 is found in the JNK pathway, which is responsible for numerous cellular functions (Johnson and Lapadat 2002) . Previous work in breast cancer tissue has identified multiple mutations along this pathway (including MAP2K4 and MAP2K7) (Koboldt et al. 2012 ) and suggests that this mutation could act as a driver by altering function of the JNK pathway. Brady et al. first identified this structural variant in MAP2K4 in this patient, but by analyzing mobile elements in these patients we have been able to better classify the cause of the mutation.
Our analysis of RNA-seq data in these patients showed very few subfamily-level expression changes for mobile elements through time. While we did not have control RNA-seq data from the germline, we were able to examine the course of expression change through tumor progression. Of the three patients with RNA-seq data, only one patient showed a subfamily-level change in expression. This was linked to an increase in HERV activity, which previous studies have reported for HERV-K in various cancers (Wallace et al. 2014; Ma et al. 2016) . We were also able to examine the expression of specific mobile element loci in which there were informative reads. Here, using the RNA-seq data that we had for Patient 2, which spanned multiple years, we showed that many loci did change expression levels over time. The majority of these elements were in non-coding regions, though some were found in regulatory regions.
Previous work has shown that changes in mobile element methylation and expression can impact nearby gene expression (Xie et al. 2013; Jang et al. 2019) . This shows that mobile elements, even at the locus level, can change expression throughout cancer progression, potentially altering the expression of one or several genes, or changing which mobile elements are capable of retrotransposition. These expression changes are likely tied to methylation changes due to the high CpG content of mobile elements (Yoder et al. 1997) . We were only able to demonstrate expression changes in Patient 2, the patient that had the most RNA-seq timepoints over the longest course of time. Future studies should examine locus-level expression over time, with germline control comparisons to determine how these expression levels compare with normal cells over longer sampling timepoints.
To our knowledge, our study is the first to examine mobile element activity in longitudinal cancer samples. We find that most mobile element insertions and the structural variation events they mediate appear to occur early in tumor development, and most of these early events appear to be passenger mutations. In addition to these passenger mutations, we find mobile element mediated SV events that disrupt the coding sequence of known (MAP2K4) and suspected (YTHDF2) driver genes in breast cancer. Though our sample size is small, we identified a number of L1, Alu, and SVA insertions occurring during tumor progression. As most studies attempt to identify only L1 insertions and L1-mediated structural variants, we may be underestimating the impact that mobile elements have on mediating driver mutations in cancer.
Future studies should examine other types of cancer for the patterns and impact of mobile element insertions that we found to determine which cancers have an increase in Alu and SVA activity, as others have done with L1 insertions. Improving our understanding of mobile element insertions and structural variation events in cancer could enhance our ability to identify tumor subclones and our understanding of the mutational landscape in cancer.
Methods

Sequencing data
Information regarding the acquisition of patient sequencing data, as well as quality control and alignment information, can be found in Brady et al. 2017. Blood-derived DNA was sequenced and used as the germline DNA sample. Tumor samples were sequenced from ascites and pleural fluid surrounding the breast tumor. DNA sequencing data had previous been aligned to hg19. Data from the Brady et al. 2017 publication are available with controlled access on the European Genome-phenome Archive (EGA) under accession EGAS00001002436.
Mobile element insertions and variants identification
We used the Mobile Element Locator Tool (MELT) (Version 2.1.5) (Gardner et al. 2017 ), RUFUS (https://github.com/jandrewrfarrell/RUFUS), where possible, and TranSurVeyor (Rajaby and Sung 2018) for the identification of mobile elements and related structural variants in our longitudinal breast cancer samples. Each of these three tools incorporates different methods for identifying variants. Insertions and variants identified by these programs were filtered to include only those that appeared absent in the germline sequencing data. To ensure that the potential mobile element insertions or mobile element mediated structural variants were, in fact, mobile element sequences, we used both BLAT (Kent 2002) and RepeatMasker (Smit 2013 (Smit -2015 . Visual inspection was performed to ensure that the sequences matched a known mobile element sequence using the Integrated Genome Viewer (IGV, Version 2.4.13) (Robinson et al. 2011 ). This step helped to prevent the inclusion of reads that had simply mis-mapped to an incorrect region of the genome. Reads that appeared to have discordant and/or split reads that mapped to a mobile element were included for further validation. Where possible, we used classic hallmarks of retrotransposition events (target site duplications and poly A tails) to ensure that we had identified an insertion. We validated candidate structural variation events that appeared to be mediated by mobile elements with Lumpy (Version 0.2.13) (Layer et al. 2014) , and we used IGV validation to identify signs of mobile element involvement. BEDTools (Quinlan and Hall 2010) intersect was used to determine if the identified variants overlapped with ultraconserved non-coding regions or regulatory elements. Ultraconserved elements and regulatory blocks locations were obtained from UCNEbase (https://ccg.epfl.ch/UCNEbase/) (Dimitrieva and Bucher 2013) . The UCSC Genome Browser was manually checked to ensure no other regulatory elements overlapped the insertion site.
Variant allele frequency
Variant allele frequency was calculated by counting the number of reads showing evidence of the insertion or variant in IGV and dividing this by the total number of reads at the breakpoint of the insertion or variant. The variant allele frequency was then adjusted by multiplying the total number of reads at the breakpoint by the tumor purity (or cancer cell fraction) value. These values were calculated using FACETS (Shen and Seshan 2016) , which utilizes SNPs in germline and tumor samples, as well as copy number changes, to provide an estimate of the proportion of tumor cells in the sample. FACETS was also used to determine the location of copy number changes throughout the genome, and particularly at the loci at which we identified variants.
RNA-seq analysis and mobile element expression
Mobile element expression was measured on a subfamily-specific level and a locusspecific level using SQuIRE (Version 0.9.9.9a-beta) (Yang et al. 2019) . We compared the first timepoint for each patient to later timepoints to understand how expression patterns changed throughout cancer progression for both subfamily-level and locus-level expression. Additionally, where possible, we compared multiple early sampling timepoints with later sampling timepoints to determine if there was a change during cancer progression. SQuIRE was run according to the documentation provided. Briefly, RNA-seq data were aligned to hg38 using STAR (Version 2.5.3 a) (Dobin et al. 2013 ); counts of gene expression and mobile element expression were then generated to quantify expression. DESeq2 (Version 1.16.1) (Love et al. 2014 ) was then used to generate calls for differentially expressed subfamilies and loci. For the locus-specific expression changes at mobile element loci, we intersected these loci with mammary epithelial tissue regulatory regions from Ensembl (Aken et al. 2016) using BEDTools.
Trinity (Version 2.8.5) (Grabherr et al. 2011 ) was run on bulk RNA-seq data from the first timepoint of Patient 1 to create a library of de novo transcripts. The resulting transcripts were aligned to the transcript of MAP2K4 using BLAT. Transcripts that aligned to MAP2K4 were further examined to determine which portions of the MAP2K4 transcript were being produced.
DNA extraction and PCR validation
For validation of our detection methods, PCR amplification was run on a potential L1 insertion in Patient 2, for whom we had blood-derived germline DNA and were able to extract DNA from cancer cells (ascites). DNA extraction was performed using Qiagen DNeasy Blood and Tissue Kit (50) (Cat No./ID: 69504). PCR amplifications of 25 ng of germline DNA and 25 ng of tumor DNA were performed in 25-µL reactions using Phusion Hot Start Flex DNA polymerase. Initial denaturation was performed for 30 seconds at 98°C, with 40 cycles of denaturation for 10 seconds at 98°C, the optimal annealing temperature of 60°C for 30 seconds, followed by a 2-minute extension at 72°C, and a final extension for 5 minutes at 72°C. The reaction was performed with a negative control (water), the tumor DNA, and the matched germline DNA. Amplicons were run on a 2% agarose gel with ethidium bromide for approximately 90 minutes at 100 V. The gel was imaged using a Fotodyne Analyst Investigator Eclipse imager. The primer set used for this reaction is listed in Supplemental Table S4 , and the corresponding gel image is shown in Supplemental Figure S2 .
Immunoprecipitation and Immunoblotting
Patient ascites samples were grown in Human Breast Epithelial Cell Culture Complete Media (Celprogen M36056-01S), and HEK293T cells were grown in DMEM with 1% pen/strep and 10% heat inactivated fetal bovine serum. Magnetic beads were crosslinked to antibody (CST # 13110 PCNA 1:50 dilution, CST #9152 MKK4, 1:50 dilution) using Pierce crosslink magnetic IP kit (ThermoFisher #88805). Cells were lysed with ThermoFisher Co-IP lysis buffer.
Crosslinked beads were added to 1000µg of protein lysate and incubated overnight at 4°C.
Immunoprecipitation was performed according to Pierce™ Classic Magnetic IP/Co-IP Kit protocol (ThermoFisher #88804). Immunoprecipitated protein was removed from the antibody/bead complex using low-pH elution. Twenty-eight ug of immunoprecipitated protein was loaded per well of NuPAGE 10% Bis-Tris protein gels. After transfer to PVDF membrane, membranes were blocked with 5% milk:PBST, then incubated with primary antibody (PCNA 1:1000, MKK4 1:500) overnight at 4°C. Blots were washed with PBST and incubated with goat anti-rabbit conjugated to HRP secondary antibody (1:1000) for 45 minutes at room temperature.
Blots were then incubated in chemiluminescent substrate enhancer for 5 minutes at room temperature (SuperSignal West Pico PLUS (ThermoFisher # 34577)). Bands were visualized using x-ray film.
